Prevention of autoimmune diabetes through immunostimulation with Q fever complement-fixing antigen

D. G. Silva; B. Charlton; W. Cowden; N. Petrovsky

doi:10.1196/annals.1288.072

Prevention of autoimmune diabetes through immunostimulation with Q fever complement-fixing antigen

D. G. Silva, B. Charlton, W. Cowden, N. Petrovsky^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

The most promising strategies for prevention of type 1 diabetes seem to be in the categories of immunomodulation (e.g., nondepleting anti-CD3, Diapep, linomide) and/or immunostimulation (e.g., QFA, BCG). We are currently undertaking a research program directed toward better understanding of immunostimulants to help maximize the likelihood of success of future human clinical trials for diabetes prevention. This program is focused on the key areas of optimization of vaccine dose and route of administration, development of surrogate immune markers, and elucidation of the mechanism of protection. The mechanism whereby QFA protects against diabetes currently is not known. The elucidation of the mechanism should help identify the optimal way in which to administer QFA to provide diabetes protection. It may also assist the development of even more potent immunostimulatory vaccines.

Original language	English
Pages (from-to)	423-430
Number of pages	8
Journal	Annals of the New York Academy of Sciences
Volume	1005
DOIs	https://doi.org/10.1196/annals.1288.072
Publication status	Published - 2003

Access to Document

10.1196/annals.1288.072

Cite this

@article{b082540b2fce4a87a9e75fe6919df949,

title = "Prevention of autoimmune diabetes through immunostimulation with Q fever complement-fixing antigen",

abstract = "The most promising strategies for prevention of type 1 diabetes seem to be in the categories of immunomodulation (e.g., nondepleting anti-CD3, Diapep, linomide) and/or immunostimulation (e.g., QFA, BCG). We are currently undertaking a research program directed toward better understanding of immunostimulants to help maximize the likelihood of success of future human clinical trials for diabetes prevention. This program is focused on the key areas of optimization of vaccine dose and route of administration, development of surrogate immune markers, and elucidation of the mechanism of protection. The mechanism whereby QFA protects against diabetes currently is not known. The elucidation of the mechanism should help identify the optimal way in which to administer QFA to provide diabetes protection. It may also assist the development of even more potent immunostimulatory vaccines.",

keywords = "Autoimmune diabetes, Immunostimulation, QFA, Type 1 diabetes, Vaccine development",

author = "Silva, {D. G.} and B. Charlton and W. Cowden and N. Petrovsky",

year = "2003",

doi = "10.1196/annals.1288.072",

language = "English",

volume = "1005",

pages = "423--430",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Prevention of autoimmune diabetes through immunostimulation with Q fever complement-fixing antigen

AU - Silva, D. G.

AU - Charlton, B.

AU - Cowden, W.

AU - Petrovsky, N.

PY - 2003

Y1 - 2003

N2 - The most promising strategies for prevention of type 1 diabetes seem to be in the categories of immunomodulation (e.g., nondepleting anti-CD3, Diapep, linomide) and/or immunostimulation (e.g., QFA, BCG). We are currently undertaking a research program directed toward better understanding of immunostimulants to help maximize the likelihood of success of future human clinical trials for diabetes prevention. This program is focused on the key areas of optimization of vaccine dose and route of administration, development of surrogate immune markers, and elucidation of the mechanism of protection. The mechanism whereby QFA protects against diabetes currently is not known. The elucidation of the mechanism should help identify the optimal way in which to administer QFA to provide diabetes protection. It may also assist the development of even more potent immunostimulatory vaccines.

AB - The most promising strategies for prevention of type 1 diabetes seem to be in the categories of immunomodulation (e.g., nondepleting anti-CD3, Diapep, linomide) and/or immunostimulation (e.g., QFA, BCG). We are currently undertaking a research program directed toward better understanding of immunostimulants to help maximize the likelihood of success of future human clinical trials for diabetes prevention. This program is focused on the key areas of optimization of vaccine dose and route of administration, development of surrogate immune markers, and elucidation of the mechanism of protection. The mechanism whereby QFA protects against diabetes currently is not known. The elucidation of the mechanism should help identify the optimal way in which to administer QFA to provide diabetes protection. It may also assist the development of even more potent immunostimulatory vaccines.

KW - Autoimmune diabetes

KW - Immunostimulation

KW - QFA

KW - Type 1 diabetes

KW - Vaccine development

UR - http://www.scopus.com/inward/record.url?scp=1942474600&partnerID=8YFLogxK

U2 - 10.1196/annals.1288.072

DO - 10.1196/annals.1288.072

M3 - Article

SN - 0077-8923

VL - 1005

SP - 423

EP - 430

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

ER -

Prevention of autoimmune diabetes through immunostimulation with Q fever complement-fixing antigen

Abstract

Access to Document

Other files and links

Fingerprint

Cite this